US 11,980,595 B2
Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
Kenji Hashimoto, Chiba (JP)
Assigned to National University Corporation Chiba University, Chiba (JP)
Appl. No. 16/969,713
Filed by National University Corporation Chiba University, Chiba (JP)
PCT Filed Feb. 14, 2019, PCT No. PCT/JP2019/005415
§ 371(c)(1), (2) Date Aug. 13, 2020,
PCT Pub. No. WO2019/160057, PCT Pub. Date Aug. 22, 2019.
Claims priority of application No. JP2018-025170 (JP), filed on Feb. 15, 2018; and application No. JP2018-121858 (JP), filed on Jun. 27, 2018.
Prior Publication US 2021/0000762 A1, Jan. 7, 2021
Int. Cl. A61K 31/135 (2006.01); A61P 1/00 (2006.01); A61P 19/10 (2006.01)
CPC A61K 31/135 (2013.01) [A61P 19/10 (2018.01)] 14 Claims
 
1. A method of preventing or treating ulcerative colitis or Crohn's disease in a subject in need thereof, comprising administering to the subject a composition comprising a compound of formula (1) or a pharmacologically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein the composition comprises less than 0.15 mol % of a compound of formula (3) compared to an amount of the compound of formula (1):

OG Complex Work Unit Chemistry
wherein in formula (1) and formula (3), X represents a hydrogen atom, a halogen atom, or a C1-C10 alkyl group that may be substituted; R1 represents a C1-C10 alkyl group that may be substituted, a C1-C10 alkenyl group that may be substituted, or a C6-C14 aryl group that may be substituted; and one or more hydrogen atoms may be substituted for deuterium atoms.